U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000024: Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module (PEESS™ v2.0)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000024: Pediatric Eosinophilic Esophagitis (EoE) Symptom Severity Module (PEESS™ v2.0)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Gastroenterology (DG)

DDT COA Number
DDT COA #000024

Instrument Name
Pediatric Eosinophilic Esophagitis (EoE) Score (PEES™ v2.0)

Disease/Condition
Eosinophilic Esophagitis (EoE)

Concept of Interest
EoE Symptoms

Context of Use
Children (2-12 years) and adolescents (12-18 years) with EoE

COA Type
ObsRO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
Marc Rothenberg

Contact(s)
Marc Rothenberg

Date Accepted into CDER’s COA Qualification Program
January 3, 2012

Submission and Regulatory Correspondence History

Qualification Submission

Date

FDA Submission Decision & Recommendations

Date

--

--

Transition Letter to 507 Process

9/5/19

Back to Top